Research programme: bispecific antibodies - Alligator Bioscience/Orion Pharma
Latest Information Update: 24 Jan 2023
At a glance
- Originator Alligator Bioscience; Orion
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 Jan 2023 Alligator Bioscience extends research and licensing agreement with Orion Corporation for second bispecific antibody
- 18 Aug 2021 Alligator Bioscience and Orion enter into a research collaboration and license agreement to discover and develop bispecific antibodies for cancer
- 18 Aug 2021 Early research in Cancer in Norway (unspecified route) in August 2021